BEGIN:VCALENDAR
PRODID:-//github.com/ical-org/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:STANDARD
DTSTART:20241103T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZNAME:EST
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250309T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZNAME:EDT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Session: Epidemiology Methods Program: Epidemiology Time: 3 - 
 3:15 PM Presenters: Anne Wyllie\, PhD Abstract Background: The “gold stan
 dard” sample for SARS-CoV-2 detection defaulted to nasopharyngeal swabs d
 ue to their use for other respiratory pathogens. However\, supply chains 
 buckled\, healthcare workers were put at risk when obtaining samples\, an
 d discomfort from invasive swabbing created testing aversion. Saliva quic
 kly emerged as a viable sample to overcome these challenges. Objective(s)
 : Saliva-based diagnostic tests enable a proactive response to potential 
 disease outbreaks\, saving valuable resources while increasing accessibil
 ity and equity. Saliva collection can also transform patient care in remo
 te or low-resource settings as a flexible tool for diagnostic testing\, s
 urveillance programs\, sequencing\, and/or monitoring vaccine impact. Met
 hods: We designed ‘SalivaDirect’ to simplify testing through: 1) demonstr
 ating the sensitivity of saliva for SARS-CoV-2 detection\; 2) developing 
 clear instructions for reliable self-collection\; 3) negating the need fo
 r healthcare worker-assisted collection\; 4) eliminating collection tubes
  with propriety buffers and/or preservatives\; 5) replacing nucleic acid 
 extraction with a simple heat and/or enzymatic step\; 6) validating reage
 nts and instruments from multiple suppliers\; and 7) establishing a novel
 \, open-source emergency use authorization (EUA) regulatory framework. Sa
 livaDirect has since been validated for the detection of influenza\, RSV\
 , and mpox\, with more targets on the horizon. Results: Advances in testi
 ng during the pandemic created new possibilities for respiratory pathogen
  detection. Approaches like SalivaDirect demonstrate that saliva can be u
 sed as a sensitive\, reliable option for not only SARS-CoV-2 detection\, 
 but other infectious diseases. Conclusion: Saliva supports effective and 
 sustainable testing approaches which merits further exploration as we loo
 k to overcome current and evolving public health challenges.\n\nAdmission
 :\nRegistrationFees: APHA Event Registration is Required\n\nDetails URL:\
 nhttps://medicine.yale.edu/event/20640-supporting-equitable-public-health
 -solutions-with-saliva-based-testing/\n
DTEND;TZID=America/New_York:20231112T151500
DTSTAMP:20260417T095108Z
DTSTART;TZID=America/New_York:20231112T150000
GEO:33.759603;-84.396873
LOCATION:285 Andrew Young International Boulevard Northwest\, Atlanta\, GA
 \, United States
SEQUENCE:0
STATUS:Confirmed
SUMMARY:2064.0 Supporting equitable public health solutions with saliva-ba
 sed testing - an innovative\, low-cost\, and scalable testing methodology
UID:8b7c0e23-68a1-4cc1-9f7c-78b19eccabb3
END:VEVENT
END:VCALENDAR